A detailed history of Seven Eight Capital, LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 35,478 shares of RARE stock, worth $1.65 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
35,478
Previous 11,760 201.68%
Holding current value
$1.65 Million
Previous $483,000 307.87%
% of portfolio
0.19%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.21 - $59.36 $953,700 - $1.41 Million
23,718 Added 201.68%
35,478 $1.97 Million
Q2 2024

Aug 12, 2024

SELL
$37.42 - $51.61 $1.34 Million - $1.85 Million
-35,796 Reduced 75.27%
11,760 $483,000
Q1 2024

May 13, 2024

BUY
$43.02 - $53.69 $70,983 - $88,588
1,650 Added 3.59%
47,556 $2.22 Million
Q4 2023

Feb 13, 2024

BUY
$31.73 - $49.19 $851,347 - $1.32 Million
26,831 Added 140.66%
45,906 $2.2 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $184,063 - $245,944
5,271 Added 38.18%
19,075 $680,000
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $515,579 - $719,878
13,804 New
13,804 $636,000
Q3 2022

Nov 10, 2022

BUY
$39.96 - $66.14 $513,565 - $850,031
12,852 New
12,852 $532,000
Q2 2022

Aug 04, 2022

SELL
$45.8 - $85.4 $159,796 - $297,960
-3,489 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$62.2 - $84.4 $217,015 - $294,471
3,489 New
3,489 $253,000
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $674,085 - $885,862
-8,651 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$92.19 - $115.71 $797,535 - $1 Million
8,651 New
8,651 $825,000
Q1 2020

May 14, 2020

SELL
$33.8 - $62.9 $498,482 - $927,649
-14,748 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$36.08 - $45.83 $966,944 - $1.23 Million
-26,800 Reduced 64.5%
14,748 $630,000
Q3 2019

Nov 14, 2019

BUY
$42.5 - $63.11 $1.77 Million - $2.62 Million
41,548 New
41,548 $1.78 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.25B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.